Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 35.2% from a year ago
Short-term investments stood at $238M at the end of Q1 FY2026, down 35.2% from a year earlier and down 8.1% from the prior quarter. Over 3 fiscal years it compounded at -25.0% a year.
Context
- Short-term investments amounted to 18.4% of total assets at the end of Q1 FY2026, down 9.6 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -35.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 259M USD
- Year-over-year change
- -40.6%
- 4-year CAGR
- -12.0%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 259M | -40.6% |
| FY2024 | 2024-12-31 | 436.3M | +20.0% |
| FY2023 | 2023-12-31 | 363.63M | -40.9% |
| FY2022 | 2022-12-31 | 614.82M | +42.1% |
| FY2021 | 2021-12-31 | 432.61M | — |
Short-term Investments vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's Mar 2026 short-term investments of $238M is the 4th highest of the 11 companies compared; the peer median is $100.83M.
- Its year-over-year change of -35.2% is the 7th highest of 9, against a peer median of +39.0%.
- Short-term investments amounts to 18.4% of total assets for RARE, versus a peer median of 34.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.18B | +21.3% | +94.4% | 36.3% | |
| Mar 2026 | $446.56M | +132.8% | +63.2% | 57.3% | |
| Mar 2026 | $318.4M | +69.4% | +28.5% | 62.1% | |
| Mar 2026 | $238M | -35.2% | -25.0% | 18.4% | |
| Mar 2026 | $135.26M | -1.8% | -9.9% | 39.6% | |
| Mar 2026 | $106.9M | +56.7% | +43.9% | 53.9% | |
| Mar 2026 | $94.77M | -64.7% | -19.8% | 33.2% | |
| Jun 2026 | $42.25M | +432.2% | -43.3% | 3.5% | |
| Sep 2026 | $0 | -100.0% | -24.0% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RARE) | $100.83M | +39.0% | +9.3% | 34.7% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 307.58M | 132.94M | 213.58M | 173.73M | 434M |
| Short-term Investments | 432.61M | 614.82M | 363.63M | 436.3M | 259M |
| Net Receivables | 44.43M | 40.45M | 73.39M | 121.8M | 159M |
| Inventory | 16.23M | 26.77M | 33.97M | 45.01M | 52M |
| Other Current Assets | 55.75M | 68.93M | 47.62M | 40.29M | 47M |
| Total Current Assets | 856.6M | 883.9M | 732.18M | 817.12M | 951M |
| Property, Plant & Equipment (Net) | 176.18M | 259.73M | 290.57M | 265.93M | 267M |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44M |
| Intangible Assets | 130.79M | 160.11M | 166.27M | 178.31M | 176M |
| Long-term Investments | 293.86M | 148.97M | 199.9M | 135M | 59M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 20.56M | 48.34M | 57.69M | 62.68M | 35M |
| Total Non-current Assets | 665.79M | 661.55M | 758.83M | 686.33M | 581M |
| Total Assets | 1.52B | 1.55B | 1.49B | 1.5B | 1.53B |
| Account Payables | 17.14M | 43.27M | 42.11M | 38.76M | 31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 81M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.61M | 1.48M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 142.79M | 87.47M | 183M |
| Total Current Liabilities | 181.37M | 261.21M | 280.44M | 344.15M | 384M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.17B |
| Deferred Tax Liabilities | 33.31M | 31.67M | 30.06M | 30.06M | 30M |
| Deferred Revenue (Non-current) | 1.47M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 352.79M | 880.26M | 874.53M | 836.91M | (4M) |
| Total Non-current Liabilities | 418.47M | 931.74M | 935.16M | 897.01M | 1.22B |
| Total Liabilities | 599.84M | 1.19B | 1.22B | 1.24B | 1.61B |
| Common Stock | 69K | 70K | 82K | 92K | 0 |
| Retained Earnings | (2.07B) | (2.78B) | (3.39B) | (3.96B) | (4.53B) |
| Accumulated OCI | (1.4M) | (6.57M) | 647K | (643K) | 1M |
| Other Stockholders Equity | 0 | 0 | 432K | 3.59M | 8M |
| Minority Interest | 0 | 0 | 0 | 7M | 7M |
| Total Equity | 922.56M | 352.49M | 275.41M | 262.3M | (73M) |
| Total Debt | 41.97M | 31.59M | 43.17M | 40.34M | 1.28B |
| Net Debt | (265.61M) | (101.35M) | (170.42M) | (133.39M) | 842M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.